Botulinum Neurotoxin (BoNT) Bioassay Plasmid Vector

RGBiotech offers the BoNT bioassay plasmid vector that is designed to establish in vitro human neuronal stable cell line models (e.g., SIMA cell) to express a modified luciferase reporter to test the activities of both the large and small subunit of BoNT. The plasmid vector contains a luciferase reporter gene with specific N-terminal sequence that redirect the luciferase into neuro-secretory vesicles. After stably delivered into the neuronal cell line, upon depolarization of the cells, the luciferase reporter is released from the cells into culture supernatants together with neuro-secretory vesicles. BoNT can inhibit the release of the luciferase reporter into the cell culture supernatants. Therefore, neuronal cell lines expressing the modified luciferase reporter can be used to sensitively detect the inhibition of depolarization-dependent reporter release by prior incubation with BoNT and serve as an alternative method to quantify BoNT activity in replacement of the use of mouse lethality assay.

Application

Read More

Botulinum Neurotoxin (BoNT) is a potent neurotoxic protein produced by the anaerobic, gram-positive bacterium Clostridium botulinum. This bacterium is widely distributed in soil, aquatic sediments, and the gastrointestinal tracts of some animals (e.g., birds, mammals). BoNT is synthesized as part of a larger protein complex (including non-toxic hemagglutinins and non-toxic non-hemagglutinins) that protects the neurotoxin from degradation by stomach acid and digestive enzymes, enabling its absorption in the gut. In addition to C. botulinum, rare strains of C. butyricum and C. baratii also produce BoNTs, though their toxicity and clinical relevance are lower.

BoNT Serotypes

To date, 8 distinct serotypes of BoNT (A, B, C1, D, E, F, G, and the recently identified H) have been characterized, with significant differences in their amino acid sequences, target species, and toxicity. Among these:
1) Serotypes A, B, E, and F are the primary causes of human botulism (a life-threatening paralytic disease), as they efficiently bind to and disrupt human neuromuscular junctions.
2) Serotypes C1 and D mainly affect animals (e.g., birds, cattle, horses) and rarely cause human illness.
3) Serotype G has only been linked to a few isolated human cases, while Serotype H (discovered in 2013) is extremely rare and considered highly toxic, though its clinical impact remains limited.
Within serotypes, there are further subtypes (e.g., BoNT/A1, A2, A3) that vary in potency, duration of action, and antigenicity—critical factors for therapeutic applications.

BoNT Preparation

The preparation of BoNT for both research and clinical use involves a series of controlled, sterile steps to ensure purity, potency, and safety. The core process is as follows:
1). Bacterial Culture: Clostridium botulinum (of a specific serotype, e.g., A or B) is cultured anaerobically in a nutrient-rich medium (e.g., casein hydrolysate, glucose) at controlled temperature (35–37°C) for 3–5 days. During culture, the bacterium produces the BoNT-protein complex.
2). Harvest and Clarification: The culture supernatant (containing the BoNT complex) is separated from bacterial cells via centrifugation or filtration (e.g., microfiltration) to remove debris.
3). Purification: The crude toxin is purified using chromatographic techniques to isolate the active BoNT:
a) Anion-exchange chromatography: Separates the toxin based on charge differences.
b) Gel-filtration chromatography: Further purifies the toxin by molecular weight.
c) Affinity chromatography: Uses specific antibodies or ligands to target and enrich BoNT, ensuring high purity (critical for clinical use to minimize immunogenicity).
4). Formulation: Purified BoNT is diluted in a stabilizing buffer (e.g., containing albumin and sodium chloride) to a standardized concentration (expressed as "Units," U). For clinical products (e.g., cosmetic or therapeutic), it is lyophilized (freeze-dried) to extend shelf life and reconstituted with saline before use.

BoNT Functions & Applications

BoNT exerts its effects by blocking acetylcholine (ACh) release at the neuromuscular junction (NMJ), leading to temporary, reversible flaccid paralysis of the targeted muscle. This mechanism underlies its dual roles in treating diseases and cosmetic applications:

1) Clinical Therapeutic Applications

2) Applications

Existing Activity Detection Methods

BoNT activity detection focuses on measuring its ability to cleave SNARE proteins (the molecular targets involved in ACh release) or induce paralysis in biological systems. Below are the main methods, along with their advantages and disadvantages:

Contact Us